William Blair Weighs in on argenx SE’s Q1 2024 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – William Blair upped their Q1 2024 earnings estimates for argenx in a research note issued to investors on Wednesday, April 17th. William Blair analyst M. Minter now anticipates that the company will earn ($0.89) per share for the quarter, up from their previous forecast of ($1.24). The consensus estimate for argenx’s current full-year earnings is ($2.10) per share. William Blair also issued estimates for argenx’s FY2024 earnings at ($2.96) EPS and FY2025 earnings at $2.78 EPS.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. The firm had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. During the same period in the previous year, the company posted ($0.70) EPS.

ARGX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $451.00 target price on shares of argenx in a research note on Thursday. Wolfe Research started coverage on shares of argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Truist Financial upped their target price on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Wells Fargo & Company increased their price objective on shares of argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. Finally, JMP Securities restated a “market outperform” rating and set a $471.00 price objective on shares of argenx in a report on Friday, March 22nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $528.16.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $360.23 on Friday. argenx has a 52 week low of $327.73 and a 52 week high of $550.76. The company has a market capitalization of $21.36 billion, a PE ratio of -70.08 and a beta of 0.65. The company has a 50 day moving average price of $387.43 and a two-hundred day moving average price of $420.57.

Institutional Investors Weigh In On argenx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust acquired a new stake in argenx in the 3rd quarter valued at $28,000. ADAR1 Capital Management LLC bought a new position in shares of argenx in the 4th quarter valued at about $27,000. GAMMA Investing LLC grew its position in shares of argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares during the period. KB Financial Partners LLC grew its position in shares of argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 45 shares during the period. Finally, Mather Group LLC. bought a new position in shares of argenx in the 1st quarter valued at about $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.